VTE Intervention

Improving recovery and return to active living

Venous thromboembolism (VTE) — includes deep vein thrombosis (DVT) and pulmonary embolism (PE) — affects 1 out every 1000 inpatients in the US and is the second leading cause of medical complications resulting in lengthening hospital stays.1,2 Annual VTE-related deaths for the USA estimates at 296,000 and 370,000 for Europe.3 

With an annual cost of USD 27.2 billion on treating initial hospital-acquired VTE events (52% as hospital-acquired preventable costs) and another USD 34.4 billion for hospital-acquired VTE reoccurrence treatments (56% as hospital-acquired preventable costs), VTE-related hospital expenses impose a heavy burden on healthcare systems.4 

Intervention reduces DVT incidences by 70%.

Every year, US healthcare treats over 600,000 VTE incidences1, most commonly for the lower extremities.5,6 

1 out of every 1000 inpatients develop DVT every year (US)

American College of Chest Physicians® recommends mechanical VTE intervention for hospitalized acutely and critically ill inpatients at a high risk of major bleeding. Effective VTE interventions significantly reduce costs, risk of reoccurrences, morbidity, and mortality.7 

DVT complications increase length of stay by 9 days.

20% to 50% of patients with proximal DVT develop post-thrombotic syndrome (PTS), and 5% to 10% progress into severe cases such as venous ulcers , which increases the length of stay by 9 days and inpatient cost to over USD 103,860, on top of existing hospital expenses.

Are you interested in this product?


  1. Heit, John A. “Epidemiology of venous thromboembolism.” Nature reviews. Cardiology vol. 12,8 (2015): 464-74. doi:10.1038/nrcardio.2015.83
  2. Geerts, William H et al. “Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).” Chest vol. 133,6 Suppl (2008): 381S-453S. doi:10.1378/chest.08-0656
  3. Lin, J et al. “Incremental health care resource utilization and economic burden of venous thromboembolism recurrence from a U.S. payer perspective.” Journal of managed care pharmacy : JMCP vol. 20,2 (2014): 174-86. doi:10.18553/jmcp.2014.20.2.174
  4. Mahan, Charles E et al. “Venous thromboembolism: annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates.” Thrombosis and haemostasis vol. 108,2 (2012): 291-302. doi:10.1160/TH12-03-0162
  5. Lindblad, B et al. “Incidence of venous thromboembolism verified by necropsy over 30 years.” BMJ (Clinical research ed.) vol. 302,6778 (1991): 709-11. doi:10.1136/bmj.302.6778.709
  6. Grant, Jonathan D et al. “Diagnosis and management of upper extremity deep-vein thrombosis in adults.” Thrombosis and haemostasis vol. 108,6 (2012): 1097-108. doi:10.1160/TH12-05-0352
  7. Guyatt, Gordon H et al. “Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.” Chest vol. 141,2 Suppl (2012): 7S-47S. doi:10.1378/chest.1412S3
  8. Kahn, Susan R. “The post-thrombotic syndrome.” Hematology. American Society of Hematology. Education Program vol. 2016,1 (2016): 413-418. doi:10.1182/asheducation-2016.1.413
  9. Trivedi, Nikunj N et al. “The Incremental Cost of Inpatient Venous Thromboembolism After Hip Fracture Surgery.” Journal of orthopaedic trauma vol. 34,4 (2020): 169-173. doi:10.1097/BOT.0000000000001675